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Abstract: 
The basis of intra-tumoral and systemic T-cell reactivity toward cancer remains 
unclear. In particular the role that peripheral stimuli play in shaping the acquired immune 
response toward cancer is still poorly understood. In this study we document the 
surfacing of systemic immunity toward a nine-residue cryptic epitope from a member of 
the Melanoma Antigen family (MAGE-12:170-178), following temporary regression of a 
single melanoma metastasis, in response to vaccination against another molecule 
(gpl00/PMell7). This emergence was unlikely to be related to unusually high expression 
of MAGE-12 by the tumor, or by the influence of analog epitopes to MAGE-12:170-178. 
Since MAGE-12 was unlikely to be expressed at sites other than the tumor, the 
demonstration of MAGE-12:170-178 reactivity in post- but not pre-vaccination 
circulating lymphocytes suggests that the systemically observed immune response was 
influenced by events induced by the vaccine at the tumor site or in draining lymph nodal 
areas. Possibly, as suggested by pre-clinical models, immunologic ignorance is the 
default response toward cancer unless unusual stimulatory conditions occur. Surfacing of 
MAGE-12 specificity occurred in association with loss of gplOO/PMel 17 targeted by the 
vaccine. This finding suggests that vaccinations might have effects beyond their intrinsic 
specificity and may trigger broader immune responses through epitope spreading by 
inducing changes within the tumor microenvironment. This may have important practical 
implication for the development of immunization strategies. 
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Introduction 
The identification of tumor antigens and the principles of immunotherapy have 
provided an excellent tool for dissecting the molecular immunology of tumor/host 
interactions (1). There has been considerable interest in the concepts of immunotherapy as 
well as multiple attempts to immunologically enhance the anti-tumor response. The 
principals of immunotherapy allow for an elegant solution to diseases for which many 
conventional treatments are non-specific and frequently inefficient. As more has become 
known about the immune system and its interactions with both self and foreign peptides, 
investigators have become more successful in shaping modalities with potential to harness 
the immune system into an effective anti-tumor response. 
Multiple vaccine-based approaches to anti-tumor therapy are currently being 
undertaken. In particular, the molecular identification of the genes encoding tumor 
antigens recognized by T cells has sparked interest in their utilization as vaccines against 
cancer. Contrary to most vaccinations, which are aimed at priming the immune system 
against future pathogens, immunizations against cancer are given as a surrogate for the 
apparent weak immunogenicity of tumors themselves (2, 3). Specific epitopes can be 
determined, frequently by isolating tumor infiltrating lymphocytes (TIL) and identifying 
the peptide/HLA complex they recognize. The specific peptide can then be synthesized, 
and injected into the patient, in the presence or absence of cytokines. These vaccines are 
simple to administer in an out-patient setting and have been shown to incur systemic 
immunity to the peptide of interest (4,5,6). Unfortunately systemic immunity does not 
always equal clinical regression of the tumor. 
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Currently used peptide vaccines are based upon two types of tumor antigens (TA); 
tumor specific antigens (TSA) and melanoma differentiation antigens (MDA). TSA are 
specific to the tumor and are generally not present in normal cells. They are frequently 
fetal antigens and are not expressed in adult cells until far along in tumorogenesis when the 
de-differentiation of the cell leads to demethylation of the genome and to expression of 
molecules which are not normally expressed (7). An example of TSA are the melanoma 
antigen family of genes (MAGE), a family of 12 genes and gene products which have been 
shown to be expressed in many melanomas. The other type of TA, MDA, are found in 
normal melanocytes and may be critical to the normal function of the cell. These 
molecules are not critical to the tumor and are frequently down-regulated as the tumor 
becomes increasingly anaplastic (11). Examples of MDA include gplOO/PMell7, and 
MART -1 /MelanA. 
Extensive trials have been undertaken using certain MDA, specifically gpl 00:209- 
217(210M), a modified form of a peptide derived from the gpl00/PMell7 molecule, 
presented in the context of HLA*A201. This peptide was analyzed on its ability to induce 
a measurable immune response, and its ability to induce tumor regression. Data from this 
study demonstrated that on the basis of in vitro immunologic assays, 91% of patients 
studied could be successfully immunized with this synthetic peptide, and 13 of 31 patients 
(42%) receiving the peptide vaccine plus IL-2 had objective cancer responses (1). Many 
patients who were HLA*A201 positive and who expressed the gpl00/PMell7 molecule 
have undergone vaccination with this peptide. 
Although gp 100:209-217(210M) vaccine has demonstrated clinical success, there 
have been many questions as to why this molecule should induce such a strong immune 
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response, and why this molecule should appear to be immunodominant over all of the 
potential antigens a cell can express. Of the millions of possible epitopes a cancer cell 
expresses, only certain ones induce specific immune responses in the host, and these 
responses can be demonstrated over and over again in a multitude of hosts (8). Questions 
about this phenomenon of immunodominance remain unanswered. Furthermore, questions 
about other antigens exist, and their potential immunogenicity if they could be expressed in 
the absence of other, more dominant antigens. 
The MAGE family of gene products became of interest to our group with the 
discovery of a TIL which recognized MAGE-12 in a melanoma metastasis of a patient 
(F001) who had been undergoing vaccinations with the gpl 00:209-217(210M) peptide 
vaccine (9). This patient’s tumor was noted to have expression of gpl00/PMell7 prior to 
vaccination, and was noted to have a good initial response to the gpl 00:209-217(210M) 
vaccine, experiencing significant shrinkage of his tumor. However, after a period of time, 
his tumor was noted to re-grow. Analysis of peripheral blood mononuclear cells (PBMC) 
demonstrated that he retained immunity to gplOO/PMell7, however, a fine needle 
aspiration (FNA) of the tumor demonstrated that it had lost expression of gpl00/PMell7 
(10). Interestingly, lymphocytes were noted to be infiltrating the patient’s tumor. Studies 
of this TIL identified MAGE-12 as the restriction element within the context of HLA 
Cw*0702. (9). 
The identification of a TSA-recognizing TIL was an unusual finding and provided 
a conceptual bridge between the MDA-directed immune reactivity commonly observed at 
tumor site and the TSA reactivity more frequently observed among circulating T cells. 
Differences in the levels of immune reactivity toward the two categories of tumor antigens 
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might be attributed to their tissue expression pattern. Some investigators, however, 
suggested that qualitative and/or quantitative differences in the way antigenic molecules 
are presented to the host might shape the immune response more significantly (2, 12, 3). 
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Statement of Purpose and Hypothesis. 
Several hypotheses attempt to explain the insurgence of reactivity toward the 
cryptic MAGE-12 epitope in this patient. First, the tumor might have been characterized by 
unusually high expression of MAGE-12 and/or HLA-Cw*0702 capable of overriding the 
commonly dominant stimulus provided by MDA (8). Second, the loss of expression of 
MDA after vaccination (10) might have allowed the unmasking of less prominent T-cell 
populations. Third, the patient’s reactivity toward MAGE-12 might have been unusually 
high due to priming by exposure to analog epitopes of MAGE-12:170-178 as suggested for 
other TA (13). Fourth, peptide analogs of MAGE-12:170-178 from other MAGE family 
genes (14) might have exerted super-agonist or antagonist action and uniquely shaped the 
immunogenicity of MAGE-12 (15). Finally, MAGE-12-specific cytotoxic T-cell (CTL) 
could have risen in response to vaccine-induced modifications of the tumor environment 
(16). These hypotheses were tested by this study. 

6 
Materials and Methods 
All experiments were performed by Ms. Lally with the exception of the 
experiments detailed in the sections labeled “Detection of Cw*0702 surface expression by 
complement dependent cytotoxicity” and “HLA phenotyping of patients and cell lines”. 
Cell lines. 
Two clones from the melanoma cell line 624-MEL (HLA-A*0201/0301, 
B* 1402/0702, Cw*0702/0802) characterized by identical pattern of MA and HLA allelic 
expression with the exception of HLA-A*0201 were used. One clone (624.38-MEL) 
maintains expression of this allele, while the other (624.28-MEL) does not due to aberrant 
splicing of the HLA-A*0201 transcript (17). A375 MEL, SK23-MEL and 293-HEK 
primary embryonic kidney cells were purchased from the American Type Culture 
Collection, Rockville, MD. 397-MEL, 537-MEL, 836-MEL, 888-MEL, 938-MEL, 1102- 
MEL, 1123-MEL, 1280-MEL, 1359-MEL, 1495-MEL are archival cell lines derived from 
surgically removed melanoma metastases (18). F001-MEL, F002-MEL and F010-MEL 
consist of early passage (<5 passages) cell lines derived from FNA of melanoma 
metastases. The B-lymphoblastoid cells, F001-EBV, were transformed from patient F001 
PBMC. All cell lines were maintained in complete medium (CM) consisting of RPMI 
1640 (Biofluids, Rockville, MD) with 10 mM hepes buffer, 100 U/ml penicillin- 
streptomycin (Biofluids), 10 pg/ml Ciprofloxacin (Bayer West Haven, CT), 0.03% L- 
glutamine (Biofluids), 0.5 mg/ml amphotericin B (Biofluids) and 10% heat-inactivated 
fetal bovine serum (Biofluids). F001-MEL cells were maintained in Iscoves (Biofluids) 
supplemented as described for CM. 293-HEK cells were maintained in DMEM (Biofluids) 
supplemented as described for CM except 7.5% FBS. Normal human epithelial 

7 
melanocytes (NHEM) generated from human foreskin were donated by Dr. Mernhard 
Herlyn (Wistar Institute, Philadelphia, PA) and expanded in melanocyte growth medium 
(MGM, Clonetics, San Diego, CA). The F001-TIL culture recognizing MAGE-12:170-178 
was generated from patient F001 (10, 9) and expanded in CM supplemented with 10% 
human AB serum (Biofluids) and 6,000 lU/ml IL-2. 
Peptides. 
Peptides were produced by solid phase synthesis techniques and solubilized in 
sterile water or dimethylsulfoxide (DMSO, Sigma, St Louis, MO) according to their 
biochemical characteristics. Peptide identity was confirmed by mass spectral analysis. The 
following peptides were used: MAGE-12:170-178 (VRIGHLYIL) and analog peptides 
from other MAGE family genes (MAGE-1: DPTGHSYVL; MAGE-2: VPISHLYIL; 
MAGE-3: DPIGHLYIF; MAGE-4a: DPASNTYTL; MAGE-6: DPIGHVYIF), MART- 
1:27-35 (AAGIGILTV, abbreviated as MART-1), gpl00:209-217 (ITDQVPFSV, 
abbreviated as g209), the modified gp 100:209-217(210M) (19) (IMDQVPFSV, 
abbreviated as g209-2M), FluMl:58-66 (GILGFVFTL, abbreviated as FluMl) and Histone 
H3.3:40-48 (RYRPGTVAL). 
TCR V p PCR analysis. 
A previously described set of 35 primers was selected to amplify 45 functional 
V|3 (10). Each primer mix was composed of 10 x PCR buffer, 1.5 mM MgCfi, 200 pM 
dNTP, 1.25 U of AmpliTaq Gold, 0.5 pi of cDNA, 0.5 pM Vp primer, 0.5 pM TC-1 
constant region primer (AYACCAGTGTGGCCTTTT), and water up to 20 pi final 
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reaction volume. PCR was run using the following protocol: initial activation of the 
enzyme at 94°C for 9 min; 10 high-stringency cycles of 94°C for 30 sec for denaturation, 
65°C for 1 min for annealing and 72°C for 1 min for elongation; 20 low-stringency cycles 
of 94°C for 30 sec, 60°C for 1 min, and 72°C for 1 min; final extension at 72°C for 10 min. 
After PCR, 6 pi of the product and 6 pi of BPB-loading buffer were mixed and run on a 
1% agarose gel for 45 min. at 150 V. The gel was stained with Vistra Green (Amersham 
Life Science Inc., Arlington Heights, IL) 1:10000 dilution in lx TBE for 50 min and 
analyzed on a Fluorlmager 595 (Molecular Dynamics, Inc. Mountain View, CA). 
Analysis of MAGE 1-12 mRNA expression in cell lines. 
Expression of MAGE 1-12 gene products was evaluated by standard RT-PCR using 
published primer sequences (14). Two pi cDNA from each cell line were PCR amplified at 
a final volume of 50 pi and overlaid with mineral oil. The final reaction mix contained 2.5 
units of AmpliTaq Gold DNA polymerase (Perkin-Elmer, Branchburg, NJ, USA) and 10 
pM of each primer in a 50 nM KCL, 1.5 mM MgCb, 25 mM Tris HCL pH 8.9 and 200 pM 
of each dNTP solution. The reactions were carried out in a Perkin-Elmer Thermocycler 
Model 9600 using the following parameters: one cycle at 96°C for 15 minutes, 30 cycles at 
96°C for 30 seconds, 62°C for 30 seconds, 72°C for one minute. Eight pi of each PCR 
product were electrophoresed through a 2% Agarose gel containing ethidium bromide and 
a 100 bp ladder (Gibco, BRL Gaithersburg, USA). The fluorescent DNA bands were 
observed on a 302-nm UV transilluminator. 
Quantitative assessment of MAGE-12 mRNA expression was evaluated with the 
ABI Prism 7700 Sequence Detection System (Perkin-Elmer) utilizing uniplex real time 
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quantitative RT-PCR (qRT-PCR). Each tube contained a TaqmanK probe that targeted a 
single gene of interest. Each probe consisted of an oligonucleotide with a 5’-reporter and a 
downstream, 3’-quencher dye. Reporter/quencher dyes were analyzed by dual analysis 
based upon the different emission wavelength maxima. Uniplex qRT-PCR was performed 
utilizing different reaction tubes for the target gene of interest and for the endogenous 
reference ((3-Actin). Probes were labeled with a reporter dye, 6-carboxyfluorescein (6- 
FAM, A,max=518 nm) quenched by 6-carboxytetramethylrhodamine (TAMRA). Cycling of 
cDNA involved denaturation at 95° C for 15 sec., and annealing/extension at 60° C for 1 
min. for a total of forty cycles. Absolute measurement of mRNA copy number was 
performed with a standard curve for each gene of interest and for (3-Actin mRNA, dividing 
the test gene amount by the housekeeping gene amount. The final value represented the 
absolute number of mRNA copies per l(f copies of P-Actin mRNA. The sets of primers 
and labeled probes used for qRT-PCR have been previously published (20) with the 
exception of MAGE-12 for which we designed the forward primer (5’- 
TGGCATCGAGGTGGTGG-3’), the reverse primer (5’-CCCAGGCAGGTGACAAGG- 
3’) and the probe (6FAM-TGGTCCGCATCGGCCACTTGTAC-TAMRA). 
Screening of normal human tissues for MAGE-12 expression. 
A 96 well plate containing IX, 10X, 100X and 1000X concentration of various 
normal tissues was analyzed (IX is approximately equal to 1 pg). The following tissues 
were studied: brain, heart, kidney, spleen, liver, colon, lung, small intestine, muscle, 
stomach, testis, placenta, salivary gland, thyroid gland, adrenal gland, pancreas, ovary, 
uterus, prostate, skin, PBL, bone marrow, fetal brain, fetal liver. The dried cDNAs were 
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dissolved in the following reaction mix: 10 pmol of each primer, 50 nM KC1, 1.5 mM 
MgCL , 25 mM Tris HC1 pH 8.9, and 200 pM of each dNTP solution and PCR reactions 
were carried as for the tumor cell lines. 
Generation of CTL by in vitro stimulation ofPBMC 
PBMC were separated from the peripheral blood of HLA-A*0201/Cw0702 
expressing patients with melanoma by centrifugation of Ficoll-Hypaque gradients and used 
as cyropreserved samples. PBMC were thawed and their systemic reactivity against 
various epitopes was assessed by repeated stimulation with 1 pM peptide administered to 
the cultures after an overnight rest (21). Twenty-four hours after cognate stimulation 600 
IU/ml of interleukin-2 were added to the cultures. Cultures were replenished of IL-2 every 
other day. Stimulation with peptide was repeated at weekly intervals by exogenous loading 
of irradiated autologous PBMC (30 gy) as antigen presenting cells with 1 pM peptide. 
Irradiated, exogenously pulsed peptides were then co-cultured with responding cells at a 
1:1 ratio. 
Tumor-reactive CTL were also generated using HLA matched cell lines as 
previously described (22), PBMC were cultured in CM supplemented with 10% heat- 
inactivated human AB serum. Either irradiated (5,500 rads) tumor cells (1:10 
stimulator/responder ratio) or peptide (1 pM) were added to 4 x 106 PBMC in 24 well 
Costar plates. The following day and every other day thereafter 300 IU/ml IL-2 (Chiron 
Co., Emeryville, CA) were added. CTL cultures were re-stimulated weekly either with 
irradiated (3,000 rads) autologous PBMC (2 x 106 cells/ml) pulsed with IpM peptide or 
irradiated tumor cells at responder/stimulator ratios ranging between 1:3 and 1:10. 

Assessment of antigen recognition by CTL 
Epitope specificity of CTL was determined by IFN-y mRNA production in 
response to 2-hour stimulation with relevant or irrelevant epitopes. cDNA from each 
culture was assayed for IFN-y production by quantitative real-time PCR (23). Absolute 
measurement of mRNA copy number was performed with a standard curve for each gene 
of interest. In each sample IFN-y mRNA levels were normalized per ICE copies of CD8 
mRNA. 
Inhibition of MAGE-12 by other MAGE peptides 
Exposure to potential agonists or antagonists was provided by 3 x 10*1 293-HEK 
cells treated with IFN-a for 24 hours to enhance HLA-Cw*0702 surface density (24) and 
pulsed for 2 hours at 37 C with 1 pM peptide. Cells were washed of excess peptide and 
exposed to 3 x 106 F001-TIL. Aliquots containing 2 x 105 TIL were removed at time zero 
and every two hours up to 6 hours and tested for IFN-y release by qRT-PCR. After 24 
hours each culture was split into two cultures. 293-HEK cells (106) pulsed with MAGE- 
12:170-178 or the irrelevant HLA-Cw*0702 binding histone H3.3:40-48 peptide were 
added to each culture. Aliquots containing 2 x 10^ TIL were removed at time zero and 
every two hours up to 6 hours from each culture and tested for IFN-y transcript level by 
quantitative real-time PCR. 
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Detection of Cw*0702 surface expression by complement dependent cytotoxicity. 
HLA*Cw0702 levels of expression were judged by Complement Dependent 
Cytotoxicity (CDC) of cell lines previously cultured with or without IFN-a(500 mg/ml) for 
48 hours. 
HLA phenotyping of patients and cell lines. 
Molecular and serological analysis of patient and cell line HLA phenotypes was 
performed by CDC, sequence-specific primer PCR or automated sequencing as appropriate 
(9). 
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Results 
Identification of MAGE-12 reactivity in TIL and circulating lymphocytes from patient 
F001 who experienced temporary regression of cancer in response to MDA-specific 
vaccination. 
F001-TIL and F001-MEL have been previously characterized (9). These lines were 
expanded simultaneously from a FNA of a melanoma metastasis that had originally 
regressed in response to vaccination with the HLA-A*0201-associated gpl 00:209- 
217(210M) peptide administered subcutaneously in incomplete Freund’s adjuvant. F001- 
MEL lacked expression of gplOO/PMell7 and other MDA and retained expression of TSA 
of the MAGE family. Twelve identical clones from that FNA (combined here as F001- 
TIL) recognized the HLA-Cw*0702 associated MAGE-12:170-178 epitope. In this study 
we tested whether the immune reactivity against MAGE-12 observed within the tumor was 
associated with detectable systemic reactivity toward the same epitope. PBMC obtained 
from the patient at the time of the FNA were stimulated with MAGE-12:170-178, MART- 
1, gpl00/PMell7 (abbreviated as g209 in the figures and text) or gpl00:209-217(210M) 
(abbreviated as g209-2M in the figures and text). The immune reactivity elicited toward 
the various TA was compared by documenting the kinetics of specific IFN-y transcription 
by various cultures in response to relevant stimulation (23) (Figure 1A). No TA-specific 
reactivity could be detected directly in PBMC. One week after the first stimulation, CTL 
cultures elicited by stimulation with g209 or g209-2M demonstrated specific expression of 
IFN-y mRNA. Specific reactivity toward either MAGE-12 or MART-l/MelanA appeared 
only after two weeks and one re-stimulation. This is not surprising since the patient had 
recently received g202-2M-based vaccine. Interestingly, the reactivity toward MAGE-12 
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paralleled reactivity toward MART-l/MelanA. Phenotypic characterization of the CTL 
induced by stimulation of PBMC with MAGE-12:170-178 demonstrated selective 
expansion of a V(37s2 identical to the Vp expressed by F001-TIL (10). This suggested that 
systemic and local responses were mediated by expansion of an identical T-cell clone. 
Expression ofTA on HLA class I alleles by F001-MEL. 
F001-MEL expressed most MDA including gp 100/Mel 17 and MART-l/Melan A 
below the threshold of recognition by high-avidity TA-specific CTL (20). However, this 
tumor cell line retained expression of most TSA (9, 10) and could be still recognized by 
F001-TIL. Here we further characterized the level of expression of MAGE family genes in 
this and other tumor cell lines (Table IA). Notably, F001-MEL expressed most of the 
MAGE family genes. The only MAGE genes not expressed by F001-MEL (MAGE-5, 7 
and 8) were not expressed by any other melanoma cell line suggesting that these genes are 
uncommonly expressed in the context of metastatic melanoma. Since the amount of 
expression of a given TA might influence its potential immunogenicity, we used 
quantitative real-time PCR to test whether F001 expressed unusual amounts of MAGE-12 
compared with other melanoma cell lines (Table IB). F001-MEL did not appear to express 
unusually high amounts of MAGE-12 transcript compared with other melanoma cell lines, 
suggesting that levels of MAGE-12 expression were not, by themselves, a factor 
responsible for the development of MAGE-12 reactive TIL in this patient. 
Since the level of HLA class I expression modulates T-cell recognition of tumor 
cells (25), it is possible that F001-MEL expressed unusually high levels of HLA-Cw*0702 
associated with the MAGE-12:170-178 recognition. CDC suggested that HLA-Cw*0702 
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surface expression was relatively higher in F001-MEL than most melanoma cell lines since 
it could be detected without preconditioning with IFN-a or IFN-y (24). However, this did 
not appear to play a critical role in eliciting F001-TIL reactivity. Other melanoma cell 
lines, characterized by undetectable levels of HLA-Cw*0702 expression by CDC could 
elicit similar IFN-y release. Of six cell lines tested, three (624.28, 624.38 and SK-23) had 
HLA-Cw*0702 surface density below the threshold of detection by CDC without pre¬ 
treatment with IFN-a and became susceptible to CDC after such a treatment. The other 
three (938-MEL 1280-MEL and F0Q1-MEL) were susceptible to CDC independent of 
IFN-a pre-treatment. However, all cell lines triggered similar levels of IFN-y expression 
when co-cultured with F001-TIL. Thus, the most significant functional difference between 
this tumor cell line and other archival cell lines was the reduced expression of MDA. 
The expression of MAGE-12 in a panel of normal tissues revealed only trace levels 
of transcript in lungs and high levels in the testis at the highest concentration of cDNA 
(approximately 1 ng). At 0.1 ng MAGE-12 expression was barely identified in lung tissue 
but was still clearly identifiable in the testis. MAGE-12 expression was not observed in 
any other normal tissue including brain, heart, kidney, spleen, liver, colon, small intestine, 
muscle, stomach, placenta, salivary gland, thyroid gland, adrenal gland, pancreas, ovary, 
uterus, prostate, skin, PBL, bone marrow, fetal brain and fetal liver (data not shown). 
Effect of antigen presentation by tumor cell lines on MAGE-12 recognition. 
To evaluate whether loss of expression of MDA by F001-MEL might have 
facilitated the detection of MAGE-12:170-178 reactivity, we repeatedly stimulated in vitro 
post-vaccination PBMC from patient F001 with allogeneic tumor cells as previously 
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described (22). PBMC received repeated stimulation in vitro with a melanoma cell line 
expressing MAGE-12, MART-l/MelanA and gpl00/PMell7 and HLA-A*0201/Cw*0702 
alleles (624.38-MEL). Parallel PBMC cultures were also performed with 624.28-MEL, a 
clone from the same cell line with identical pattern of expression of TA and HLA- 
Cw*0702 but that had lost expression of HLA-A*0201, the molecule associated with the 
presentation of the MDA-derived immunodominant epitopes. The purpose of this 
experiment was to test whether lack of stimulation with supposedly “immunodominant” 
epitopes of gplOO or MART-1 could facilitate the identification of other cryptic epitopes. 
Since MART-1 and gplOO immune dominance has been principally associated with 
peptides presented in the context of HLA-A*0201, we selected two clones, 624.28 and 
624.38, that express identical amounts of MART-1 and gplOO. Both were derived from 
624-MEL, however 624.28 has lost expression of HLA-A*0201 and cannot present 
peptides in the context of this molecule(17). In our opinion this model has the advantage of 
subtracting the expression only of the gpl00-HLA-A*0201 and the MART-l/HLA- 
A*0201 associated epitopes maintaining the immunogenic potential of these two antigens 
in association with other HLA alleles shared with the patient’s PBMC (HLA-B*0702 and 
Cw*0702). In three separate experiments, stimulation of PBMC with 624.28 allowed 
detection of MAGE-12-specific, but not MART-l/MelanA-specific, CTL that could 
recognize the parental 624-MEL cell line (Figure 2, gray bars). In parallel experiments 
PBMC stimulated with 624.38 failed to demonstrate MAGE-12 specificity, developed 
MART-l/MelanA reactivity and could also recognize 624-MEL (Figure 2, white bars). 
The recognition of 624-MEL by the 624.28-MEL induced, but not the 624.38-induced, 
CTL could also be enhanced by pulsing with MAGE-12:170-178. Thus, the lack of 
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induction ot HLA-A*0201 -associated activity in 624.28-elicited cultures might have 
facilitated the detection of reactivity toward MAGE-12:170-178, most often masked by the 
coexistence ot HLA-Cw*0702 and HLA-A*0201 within the same ancestral haplotype (26). 
Immune reactivity toward MAGE-12 in HLA-Cw*0702 bearing individuals with metastatic 
melanoma. 
MAGE-12:170-178 immune reactivity in patient F001 was then compared to that of 
three other HLA-A*0201/-Cw*0702-expressing patients with advanced melanoma who, 
unlike patient F001, were vaccine-nai've. PBMC from F001 and the other patients were 
repeatedly stimulated with MAGE-12:170-178 and the HLA-A*0201 associated Flu 
Ml:58-66 epitope, an irrelevant peptide (Figure 3). Although it was possible to elicit brisk 
FluMl-specific responses in all patients, MAGE-12:170-178-specific responses could be 
detected only in patient F001. 
Epitope spreading following successful vaccination with a MDA-specific epitope induces 
MAGE-12:170-178 reactivity. 
To evaluate whether the unusual detection of a MAGE reactive TIL was related to 
the recent vaccination, we compared MAGE-12 recognition by PBMC obtained from 
patient F001 before and after the treatment had induced temporary tumor regression. This 
was done by comparative in vitro stimulation of pre- and post-vaccination PBMC with the 
MAGE-12:170-178 peptide. In three consecutive experiments we could not induce 
MAGE-12 reactivity in PBMC obtained before vaccination. However, we consistently 
identified MAGE-12:170-178-specific reactivity in PBMC obtained after two vaccinations 
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with g209-2M that had caused a dramatic, although temporary, shrinkage of the tumor 
(Figure IB). This data suggests that during the period lasting from when the pre¬ 
immunization sample and the post-immunization samples were obtained, a stimulus 
secondary to the vaccination induced an increase in circulating precursor T-cells capable of 
responing to in vitro stimulation with MAGE-12:170-178. Since only the tumor tissues 
expressed MAGE-12, it is reasonable to suggest that the enhancement of MAGE-12 
reactivity in circulating T-cells was related to events occurring within the tumor 
environment in response to the vaccine. 
MAGE-12:170-178 analog peptides from other MAGE-1 genes do not interfere with 
MAGE-12:170-178 immunogenicity. 
We then tested whether various MAGE family genes encompassing peptide 
sequences analogous to MAGE-12:170-178 could interfere in MAGE-12 immunogenicity. 
All of the members of the MAGE family have sequences which are homologous to 
MAGE-12:170-178. In particular, MAGE-2 and MAGE-3 have sequences which differ in 
only two to three residues from MAGE-12:170-178 and these differences are compatible 
with the HLA-Cw*0702 binding motif (9). Assuming similar binding affinity of these 
homologous sequences to HLA-Cw*0702, it is possible that these natural analogs might 
exert agonist or antagonist effects on MAGE-12:170-178 stimulatory properties, as has 
been shown for other artificial analog peptides in the context of MART-l/MelanA (13, 15). 
As a consequence, different patterns of MAGE gene expression by various tumors might 
contribute to global differences in immune reactivity toward determinants sharing 
sufficient homology. To test the possibility of interference of these epitopes with F001-TIL 
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reactivity, we co-cultured this TIL with 293-HEK cell line (pretreated with IFN-a to 
induce HLA-Cw*0702 expression) which was pulsed with 1 pM concentrations of analogs 
from MAGE-1, MAGE-2, MAGE-3, MAGE-4a and MAGE-6. Lack of interference in 
recognition of MAGE-12:170-178 would exclude competitive or synergistic effects of the 
peptides whether due to lack of binding to HLA or to direct agonistic/antagonistic effects. 
None of the analogs could stimulate F001-TIL. To test for MAGE-12:170-178 antagonism, 
F001-TIL was exposed to various analogs pulsed onto IFN-a treated 293-HEK cells for 24 
hours. TIL were then re-exposed to MAGE-12:170-178 or an HLA-Cw*0702-associated 
control epitope (histone H3.3:40-48). No modulation of IFN-y transcription in response to 
stimulation with the cognate MAGE-12:170-178 was produced by any of the analogs (data 
not shown). Thus, it is unlikely that competing analogs from other MAGE family gene 
products play a significant role in modulating MAGE-12 responses in this or other 
patients. 
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Discussion. 
The frequent identification of MART-l/MelanA and gpl00/PMell7 reactive CTL 
from patients with metastatic melanoma expressing HLA-A*0201 suggests that these TA 
may play an “immune dominant” role in the context of this HLA class I restriction 
element. In particular, MART-l/MelanA immune dominance is restricted to a unique 
epitope (MART-1:27-35) and the molecular basis for this phenomenon remains unclear 
(8). Conflicting theories have been evoked to explain the predominant role that this TA 
seems to play. We noted that MART-l/MelanA reactivity is more readily elicited in 
patients with melanoma compared with normal individuals (27). This finding suggested 
that tumors can prime the host immune reactivity and, since MART-l/MelanA is also 
expressed by normal melanocytes, that the tumor microenvironment might provide a 
quantitatively and/or qualitatively stronger stimulus for the host immune system than the 
epidermis. Others confirmed this finding and suggested that differences in immune 
reactivity between normal and melanoma bearing individuals correlate with a respective 
predominance of naive and memory CTL in the two populations (28, 29). 
Loftus et al. (13) suggested that MART-1:27-35 immune dominance might be 
explained by biochemical commonalties shared by MART-1:27-35 and analog epitopes to 
which individuals might become repeatedly exposed during their life time. Others have 
suggested a central explanation for MART-l/MelanA immune dominance. MART-1:27-35 
is a peptide sequence characterized by low affinity for HLA-A* 0201 and, therefore, 
negative TCR selection toward this epitope might be less strictly enforced during 
embryogenesis (21). 
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It is now clear that immune reactivity toward cancer can be influenced by 
peripheral stimuli artificially provided in the form of wild type or modified epitope 
determinants (25, 30). This is well illustrated by the acquisition of gpl00/PMell7 
reactivity by patient F001 in response to vaccination. However, evidence that human 
tumors can naturally shape the host immune reactivity has remained indirect (8, 28, 29). 
Pre-clinical models suggest that epitope spreading occurs in association with tumor 
rejection following vaccination with a single immunodominant CTL epitope (16). Thus, 
under immune-mediated perturbations of the tumor microenvironment, an additional signal 
is induced that complements the weak signal ordinarily provided by TA-bearing cancer 
cells (2). Antigen spreading, however, has never been demonstrated to occur in response to 
anti-cancer treatments in humans. This study documents the positive conversion of a 
patient’s immune reactivity toward a TSA (MAGE-12) following successful vaccination 
utilizing a single epitope from another TA (see Figure 1 b). Since MAGE-12 is not 
expressed in normal tissues (31), this finding can best be explained by priming of the 
immune system by vaccine-induced inflammatory reactions within the tumor. 
Alternatively, tumor antigens shed by dying tumor cells could have been transported to 
regional lymph nodes where this induction could have occurred. Since it is not known 
whether MAGE-12 was expressed by the tumor before vaccination, it cannot definitively 
be concluded that the only change occurring during treatment was related to co-stimulatory 
factors. However, MAGE-12 is expressed in approximately 80% of melanoma metastases 
and the short-term kinetics of its expression in response to immune manipulation appears 
to be extremely stable (32). The expression of the associated HLA-Cw*0702 allele might 
have played a role in the emergence of this unusual reactivity. However, increases in the 
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constitutive expression of HLA alleles are unusual in cancer unless an altered cytokine 
microenvironment (i.e. increased IFN-y levels) could have been induced by immune cells 
accrued by the vaccine. 
The most significant implication of this study is that tumor microenvironment or 
the draining lymph nodes can influence, under appropriate conditions, the host immune 
reactivity and that systemically documented immune reactivity is a vestige of a past 
immunogenic eruption. CTL elicited from PBMCs shared TCR utilization with F001-TIL 
suggesting a common origin for the tumor-reactivity seen in this patient (10). It remains 
unclear how the tumor cells, whose immunogenicity resounded systemically, could escape 
the immune effects they created. To the best of clinical testing, this patient was the bearer 
of only this tumor mass suggesting that the immune reactions caused by the vaccine 
converged in the lesion studied. It is possible that upon temporary disappearance of the 
lesion the priming conditions created by the vaccine extinguished and failed to sustain a 
clinically effective immune reactivity. Exogenous sustenance of such reactivity by 
vaccines might provide the continuity of stimulation that the tumor microenvironment 
seems to lack. The demonstration of epitope spreading may have also practical 
implications because it suggests that alternatives are available when loss of TA targeted by 
vaccines occurs. In particular, the identification of MAGE-12:170-178 might be of broader 
significance than previously suspected as this epitope has recently been shown to play a 
role as antigen in cancers other than melanoma (33). 
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Figure legends 
Figure 1. A. Detection of epitope-specific IFN-y transcript by quantitative real-time PCR 
in PBMC (time 0) and CTL cultures (at various time points) obtained from patient F001 
after two subcutaneous administrations of g209-2M peptide in incomplete Freund’s 
adjuvant. CTL were sensitized in vitro by repeated weekly exposure to 1 pM MAGE- 
12:! 70-178, MART-1:27-35, g209 or g209-2M peptides and interleukin-2 (300 IU/ml). 
Epitope-specificity was tested by exposing the T-cell cultures to relevant and irrelevant 
(Flu Ml :58-66) 1 pM peptide for two hours before preparation of cDNA for assessment of 
IFN-y transcript by quantitative real-time PCR. The labels describe the peptide used for 
PBMC induction / peptide used for specificity testing. Data are presented as average of 
four experiments + SEM. Student t-test p-value for data after a second and third in vitro 
sensitization are all < 0.001 when relevant (solid symbols) stimulation is compared to the 
respective irrelevant (open symbols) stimulation with Flu. B. Detection of epitope-specific 
IFN-y transcript by quantitative real-time PCR in PBMC obtained from patient F001 
before and after vaccination with g209-2M peptide in incomplete Freund’s adjuvant as in 
panel A. PBMC were sensitized in vitro by repeated weekly exposure to MAGE-12:170- 
178, g209 and g209-2M peptides and interleukin-2 (300 IU/ml). Epitope-specificity was 
tested by exposing the T-cell cultures to 1 pM peptide for two hours before preparation of 
cDNA for assessment of IFN-y transcript. In both panels, results are normalized as IFN-y 
mRNA copies per 106 CD8 mRNA copies (23). Data are presented as average of four 
experiments ± SEM. Student’s t-test p-value for pre- vs. post-vaccination culture results < 
0.001 for all specificities presented. 
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Figure 2. Modulation of epitope-specific T-cell induction by stimulation with melanoma 
cells expressing different HLA class I alleles. Patient F001 PBMC were stimulated weekly 
in presence of IL-2 (300 IU/ml) with the HLA-A*0201 and Cw*0702 expressing cell line 
clone 624.38 MEL (white bars) or a clone (624.28 MEL) characterized by HLA-A*0201 
allelic loss (17) but retaining expression of Cw*0702 (gray bars). These clones have been 
previously characterized and express similar amounts of MART-l/MelanA and MAGE-12. 
After three stimulation the cultures were tested by two-hour exposure to 1 pM MART- 
1:27-35, lpM MAGE-12:170-178 or to 624-MEL pretreated with IFN-a (500 pg/ml x 48 
hours) to enhance HLA class I molecule expression. In addition, 624-MEL was pulsed 
with lpM MAGE-12:170-178 (624-MEL + MAGE). Results are presented as ratio of 
IFN-y mRNA copies per 106 CD8 mRNA copies in tested sample over the same parameter 
in cultures not exposed to peptide. Data are presented as average of three experiments + 
SEM. Student t-test p-value comparing cultures induced with 624.28 with those induced 
with 624.38 are as follows: <0.05 for MART-1, <0.001 for MAGE-12, non-significant for 
624-MEL and <0.01 for 624-MEL exogenously loaded with 1 pM MAGE-12:170-178 
peptide 
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Figure 3. Induction of MAGE-12:170-178 reactivity in PBMC from four HLA-Cw*0702 
expressing patients with metastatic melanoma. PBMC from four patients with metastatic 
melanoma expressing HLA-Cw*0702 (as well as HLA-A*0201) were stimulated weekly 
with lpM MAGE-12:170-178 peptide or lpM Flu ME58-66 peptide and interleukin-2 
(300 IU/ml). Patient # 1 is F001. Epitope-specificity was tested by exposing the T-cell 
cultures to lpM MAGE-12:170-178 or Flu ME58-66 peptide for two hours before 
preparation of cDNA for assessment of IFN-y transcript by quantitative real-time PCR. 
Results are presented as IFN-y mRNA copies per CD8 mRNA copies in tested sample 
over the same parameter in cultures not exposed to peptide. Data are presented as average 
of three experiments ± SEM. 
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Table I 
Quantitative and qualitative assessment of MAGE gene expression in melanoma cell lines 
A e 
Cell Line 
1 2 3 4a 
MAGE protein 
5 6 7 8 9 10 11 12 
MAGE 12 
NHEM 1 
F001-MEL + + + + + - - + + + + 590 
F001-EBV 4 
F002-MEL + + + + + - - - + + + 4700 
F010-MEL - + + - + n.d. n.d - - - + 1200 
397-MEL + + + - + - - + + + + 3800 
537-MEl + + + + + - - - + - + 1500 
624.28- + + + + + - - + + + + n.d. 
624.38- + + + + + - - + + + + 1500 
836-MEL + + + + + - - - + + + 1100 
888-MEL + + + - + - - + + - + n.d. 
938-MEL + + + + + - - + + + + 1000 
1102-MEL - + + + + - - - - - + 550 
1123-MEL - - + - - - - - - - - 15 
1280-MEL - + + - + - - - - - + 15 
1359-MEL - + + - + - - - - - + 51 
1495-MEL + + + + + - - + + + + 1850 
A375-MEL + + + + + - - - + + + 250 
SK-23- - + + - + - - - - - + 1200 
A. The identity of amplified products was confirmed by sequencing using PCR products from 
F001-MEL. (n.d. = not done) 
B. Expression of MAGE-12 mRNA copies was measured quantitatively by real-time PCR as 
MAGE-12 mRNA copy number over p-Actin mRNA copy number. Data were further normalized 
by providing a ratio of MAGE-12/p-Actin transcript levels in cell lines over that of normal human 
epithelial melanocytes (NHEM). Each sample was analyzed in duplicate and average values are 
presented. 
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